SCHEMBL24256846

SCHEMBL24256846

CCCc1nc2sc3c(NCCc4ccc(N5CCNCC5)cc4)ncnc3c2c2c1CCC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
RAD52 P43351 3/20 0.49
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 5/20 0.49
POLB P06746 5/20 0.49
LMNA P02545 4/20 0.49
HTT P42858 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HPGD P15428 2/20 0.48
ADRB2 P07550 1/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 1/20 0.47
TSHR P16473 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 2/20 0.45
MAPK1 P28482 2/20 0.45
IDE P14735 1/20 0.45
UBE2N P61088 1/20 0.45
RXFP1 Q9HBX9 2/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256699 0.83 KDM4E (0.49) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256695 0.83 KDM4E (0.53) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256352 0.81 POLB (0.51) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256356 0.80 NPC1 (0.48) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256613 0.80 RAD52 (0.47) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256706 0.79 NPC1 (0.49) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256420 0.78 KDM4E (0.73) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256614 0.77 HTT (0.55) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256693 0.77 KDM4E (0.46) KMT2ARAD52ALDH1A1KDM4EPOLB
SCHEMBL24256416 0.77 KDM4E (0.66) KMT2ARAD52ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 KMT2A 1456/4885RAD52 1460/4885ALDH1A1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.